Wong O
Applied Health Sciences, Inc., San Mateo, California 94401, USA.
Regul Toxicol Pharmacol. 1996 Feb;23(1 Pt 1):74-85. doi: 10.1006/rtph.1996.0011.
Concerns regarding the possible role of breast implants (particularly silicone breast implants) in the development of connective tissue diseases were raised by case reports of connective tissue diseases in women with breast implants. Case reports, however, are not appropriate for causation assessment. Within the past few years, epidemiologic studies have begun to appear. Based on a comprehensive literature search, 15 epidemiologic studies on breast implants and connective tissue diseases, which satisfied certain basic epidemiologic requirements, were included in the critical assessment. These studies utilized either the case-control or the cohort study design. Although each individual study was relatively small, and the statistical power to detect a modest risk increase in specific categories of connective tissue diseases was limited, the results of these studies, however, were strikingly consistent, particularly those reported in case-control studies. To increase statistical power and to take the consistency of results into consideration, meta-analyses were used to summarize results from individual studies quantitatively. Based on data from case-control studies, meta-analyses of rheumatoid arthritis, systemic sclerosis (scleroderma), and systemic lupus erythematosus were performed. These case-control studies represented a combined database of approximately 4000 cases of connective tissue diseases, and the power was sufficient to detect a relatively small increase in risk. Based on the meta-analyses, the relative risks (95% confidence intervals) were 0.85 (0.48-1.51) for rheumatoid arthritis, 0.82 (0. 50-1.35) for systemic sclerosis, and 0.33 (0.06-2.03) for systemic lupus erythematosus, indicating that there was no increased risk of connective tissue diseases associated with breast implants. The findings derived from the meta-analyses of case-control studies were supported by results from cohort or prospective studies. It was concluded that epidemiologic data did not provide any evidence for a causal relationship between silicone breast implants and connective tissue diseases.
乳房植入物(尤其是硅胶乳房植入物)在结缔组织疾病发生过程中可能扮演的角色引发了人们的担忧,这是由植入乳房植入物的女性患结缔组织疾病的病例报告所引起的。然而,病例报告并不适合用于因果关系评估。在过去几年中,流行病学研究开始出现。基于全面的文献检索,15项关于乳房植入物与结缔组织疾病的流行病学研究被纳入批判性评估,这些研究满足了某些基本的流行病学要求。这些研究采用了病例对照或队列研究设计。尽管每项单独的研究规模相对较小,检测特定类型结缔组织疾病中适度风险增加的统计效力有限,但这些研究的结果却惊人地一致,尤其是病例对照研究中报告的结果。为了提高统计效力并考虑结果的一致性,采用了荟萃分析来定量总结各个研究的结果。基于病例对照研究的数据,对类风湿关节炎、系统性硬化症(硬皮病)和系统性红斑狼疮进行了荟萃分析。这些病例对照研究代表了一个约4000例结缔组织疾病病例的综合数据库,其效力足以检测到相对较小的风险增加。基于荟萃分析,类风湿关节炎的相对风险(95%置信区间)为0.85(0.48 - 1.51),系统性硬化症为0.82(0.50 - 1.35),系统性红斑狼疮为0.33(0.06 - 2.03),这表明乳房植入物与结缔组织疾病之间不存在风险增加的情况。病例对照研究荟萃分析得出的结果得到了队列研究或前瞻性研究结果的支持。结论是,流行病学数据没有提供任何证据表明硅胶乳房植入物与结缔组织疾病之间存在因果关系。